Venus Remedies receives Saudi Arabia’s marketing approval for anti-coagulant drug

The Saudi Food and Drug Authority (SFDA) granted Venus Remedies marketing approval for the anticoagulant medication Enoxaparin. The approval follows the company's receipt of the foreign medicine regulator's certification of good manufacturing practices for its plant in Himachal Pradesh six months ago.

Enoxaparin is an important drug for avoiding blood clots among patients with diseases including deep vein thrombosis, acute coronary syndrome, pulmonary embolism, and life-threatening disorders like heart attack. The sale of the product in pre-filled syringes has been given marketing approval by this company.

“The Enoxaparin market size of Saudi Arabia was USD 35 million in 2022 and is estimated to reach USD 40 million by 2025, expanding at a CAGR of 5 percent. We have so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products,” the company said in a regulatory filing.

Manufacturing pharmaceuticals is a business that Venus Remedies is involved in. The company specializes in creating diverse therapeutic formulations, such as antibiotics, oncology drugs, and critical care medications.

Source: Media Reports